Ligand Binding Assays (LBA)

KCAS Bio’s LBA scientists work with you to develop ligand binding assay methods from early discovery through clinical studies, with the platforms and expertise to match each assay to the question it needs to answer.

What Are Ligand Binding Assays?

Ligand Binding Assays:

Ligand binding assays (LBAs) measure interactions between two molecules: a ligand and its receptor, a monoclonal antibody and its target, or a biologic and anti-drug antibodies (ADA). They detect and quantify these molecules directly in biological samples such as plasma, serum and tissue, so they are used throughout the development of new biological entities to show how a drug behaves in the body and how it affects a living organism.

The signal in an LBA comes from specific binding, so the quality of the binding reagents largely determines whether an assay meets its purpose.

See how we develop and run LBA methods at KCAS Bio

Core formats and detection technologies

Core formats

Sandwich: a capture reagent and a detection reagent bind the same analyte.
Bridging: one analyte (such as an ADA) binds a labeled drug at both ends, linking capture and detection.
Competitive: the analyte competes with a labeled analog for a limited number of binding sites.
Cell-based: a response from living cells is read in place of, or alongside, binding.

Ultra-sensitive and multiplexed detection

Detection technology determines how much an assay can measure. Newer platforms extend sensitivity and multiplexing beyond what conventional plate-based formats offer:

Single-molecule detection (Simoa and SMCxPro): these platforms detect individual immunocomplexes instead of an averaged signal, which supports very low-abundance targets.
NULISA (Argo HT): a sandwich immunoassay that uses DNA-tagged antibodies and a sequencing readout, which allows many proteins to be measured together at high sensitivity.

From exposure to immune response: the questions our assays answer

Each step in understanding a biologic raises a different question and calls for a different assay. The data are most useful when read together.

Pharmacokinetics (PK) & Toxicokinetics (TK)

Pharmacokinetics (PK)

The question: How much drug is circulating, and for how long?
How it works: Binding reagents capture and detect the drug in plasma, serum or tissue. The result is read against a calibration curve.
The challenge: Matrix interference, non-specific binding and cross-reactivity all affect an assay’s performance. Careful reagent selection and characterization address them. Generic assays can shorten development for nonclinical studies, and drug-specific assays give more control later in a program.
Platforms: ELISA, MSD and other platforms matched to sensitivity and sample-volume needs. Hybrid LC-MS/MS is an alternative when reagents are limited.
What you get: Exposure data to support dosing decisions.

Toxicokinetics (TK)

The question: Is exposure in the toxicology species adequate and well characterized?
How it works: The same quantitation principle as PK, applied to nonclinical studies, often under GLP.
The challenge: Species-specific matrices, a wide range of drug concentrations across dose groups, and the possible effect of ADA on exposure.
Platforms: The same LBA platforms as PK.
What you get: Exposure data that put toxicology findings in context.

Target engagement

The question: Is the drug binding its target?
How it works: Assays measure free target, total target, or drug-target complexes in biological fluids.
The challenge: Distinguishing total, free and bound forms. Drug binding can change what an assay detects, so reagent choice and format need careful design.
Platforms: MSD, Ella, Simoa, SMCxPro and other platforms, depending on target abundance.
What you get: Evidence that the drug engages its target, linked to dose and exposure.

Pharmacodynamic response

Biomarkers and pharmacodynamics (PD)

The question: Is the biology changing as expected?
How it works: Soluble biomarkers are quantified individually or in multiplexed panels.
The challenge: Low-abundance targets need optimized capture and detection reagents and sensitive platforms. Assays must also fit the context of use, which is where the choice between off-the-shelf and customized assays matters.
Platforms: MSD, Luminex for multiplexing, Ella, Simoa, SMCxPro and NULISA.
What you get: Pharmacodynamic readouts to support dose selection, mechanism confirmation and efficacy assessment.

Cellular response

Functional assays

The question: Does the drug produce the intended biological effect?
How it works: Cell-based assays read a response from living cells, which complements what binding assays show.
The challenge: Living systems add variability, so these assays need careful control and characterization.
Platforms: Cell-based assay formats with plate-based readouts.
What you get: Activity data that complements exposure and binding data in PK/PD workflows.

Immune cell response

The question: How do immune cells respond to the drug or vaccine?
How it works: ELISpot counts the individual cells secreting a cytokine. Cytokine levels in the sample can also be measured on LBA platforms.
The challenge: Cell viability and sample handling affect results.
Platforms: ImmunoSpot ELISpot reader, and cytokine measurement on MSD and Luminex.
What you get: Cellular response data, including for vaccine programs.

Immunogenicity

Anti-drug antibodies (ADA)

The question: Is the immune system responding to the drug?
How it works: ADA assays detect antibodies against the biologic, typically in a tiered approach that moves from screening to confirmation and characterization.
The challenge: Interference from circulating drug and other matrix components, which is assessed during method development and validation.
Platforms: Plate-based and cell-based formats, chosen for the program.
What you get: Immunogenicity data to interpret PK and PD results and to support regulatory submissions.

Planning an LBA strategy for your biologic? Our scientists can help you decide where to start.

Start a Conversation

Choosing the right platform

There is no single best LBA platform. The right choice depends on the project’s specifications, constraints and context of use. We start with five questions:

How abundant is the analyte? Very low-abundance targets point to ultra-sensitive platforms such as Simoa, SMCxPro and NULISA.
How many analytes do you need from one sample? Multiplexed platforms such as Luminex, NULISA and MSD measure several at once.
How much sample do you have? When sample is limited, NULISA can measure many proteins from a small sample, and AlphaLISA offers a low-volume, no-wash workflow for discovery and nonclinical work.
How many samples, and how fast? Large clinical studies benefit from automated platforms and liquid handling (Hamilton, Tecan). Shorter timelines may favor automated systems such as Ella.
What is the study’s duration and stage? A method for a long program needs a plan for reagent management and bridging from the start.

If reagents are limited, or you need sequence-level or structural detail, hybrid LC-MS/MS may be the better choice.

LBA platforms at a glance

Platform	Best suited for	Multiplexing	Key features
ELISA	Established PK, PD and ADA assays	Single-plex	Plate-based; automation supports throughput
MSD (ECL)	PK, PD biomarkers and ADA	Multiplex formats available	Electrochemiluminescence detection
Luminex	Multi-analyte biomarker panels	Yes, bead-based	Built for multiplexing
Ella	Automated assays with short turnaround	Cartridge-dependent	Automated immunoassay system
AlphaLISA	Biomarker and protein detection in discovery, translational and nonclinical programs	Single-plex	Bead-based, no-wash workflow; low sample requirement; broad dynamic range
Simoa (HD-X)	Very low-abundance proteins	Single-plex and limited multiplex formats	High sensitivity; digital, bead-based detection
SMCxPro	Very low-abundance proteins	Single-plex	High sensitivity; single-molecule counting
NULISA (Argo HT)	Low-abundance biomarkers, including from limited samples	Single-plex to high-plex	High sensitivity; efficient with low sample volumes

KCAS Bio’s Ligand Binding Assay Instrumentation and People

At KCAS Bio, LBAs have been a core activity for over 10 years. We offer a plethora of instrumentation allowing to provide the pertinent solution that best suits your project’s specifications, constraints, and Context of Use (CoU), including multiple parameters for complex assays, high/ultra sensitivity, low sample volumes, short turnaround time and high throughput, as well as study duration.

We can guide your LBA-based project plan and anticipate your needs, by helping you elaborate a robust strategy for critical reagent management and bridging throughout the course of your study and the evolving needs of your drug development journey.

With our deep experience in LBA, our large technological park, our highly trained & fully engaged personnel, and the large panel of approaches, we work hand-in-hand with our clients to develop LBA methods – from the early discovery stage to their clinical studies.

At KCAS Bio, we combine technical expertise and capabilities with state-of-the-art operational infrastructure so that we can scale and adapt quickly to the needs of your project.

'Quality by design' drives every aspect of our work. Our facilities, security and IT infrastructure ensure your samples remain protected at all times, while cultivating excellence and innovation among our scientists.

Explore our labs & locations

Equipment People

Our equipment

Our people

Reagent management and regulatory readiness

Reliable assays start with well-characterized reagents. Assessing reagent specificity has a large effect on whether a method meets its objective. We help build a strategy for critical reagent management and bridging across a study, so assay performance stays consistent as programs advance and as reagent lots change.

See how we develop LBA methods

Methods are developed for regulated use. Matrix interference, non-specific binding and cross-reactivity are assessed during development. As a drug advances, the assay may need further characterization so the team understands its strengths, its limitations and how to interpret results. Validation covers accuracy, precision, specificity and robustness, in line with regulatory guidance for GLP and GCP studies.

See our quality commitment

Support from discovery through clinical studies

KCAS Bio supports development programs from early discovery through nonclinical and clinical studies, including large-scale clinical programs. Our scientists work with you to plan assays that fit your molecule and stay aligned with regulatory guidance as your program advances.

Talk to an expert

Ligand Binding Assays FAQs

How do you develop assays for low-abundance biomarkers?

We optimize capture and detection reagents, use sensitive platforms, and refine assay conditions to detect and quantify low-abundance targets while minimizing background.

How do you handle anti-drug antibody interference?

We assess ADA impact during method development and validation. Mitigation can include assay redesign, more selective reagents, or alternative formats, so accuracy is preserved.

When do you need a cell-based assay instead of a binding assay?

When binding alone doesn’t show whether the drug is active, or when you need to read a biological response.

Which detection platforms do you recommend for different targets?

Platform choice depends on target abundance, sensitivity needs and study scope. Options include ELISA, MSD, ultra-sensitive platforms and multiplexed systems.

How do you choose between a generic and a drug-specific PK assay?

Generic assays can shorten development and are often used for nonclinical studies. Drug-specific assays give more control as a program advances toward the clinic.

What is the difference between free and total target measurements?

Total target includes target both bound and unbound to drug. Free target is the unbound portion. Which one you need depends on the question, and reagent design determines which form the assay detects.